BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced an oral presentation on galeterone at the 2016 American Urological Association (AUA) Annual Meeting in San Diego. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistant prostate cancer.
